Collaboration and Licensing Agreements - Narrative (Details) $ in Thousands, ¥ in Millions, $ in Millions	1 Months Ended			3 Months Ended			12 Months Ended				32 Months Ended	97 Months Ended	98 Months Ended
	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2025 JPY (¥)	Mar. 31, 2025 USD ($)	Dec. 31, 2025 USD ($) payment_tranche	Dec. 31, 2025 CAD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2025 USD ($) payment_tranche	Dec. 31, 2025 USD ($) payment_tranche	Dec. 31, 2025 USD ($) payment_tranche	Dec. 31, 2025 JPY (¥) payment_tranche	Jun. 30, 2025 USD ($)	Apr. 30, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues							$ 407,320		$ 333,615	$ 124,456
Non-cash royalty revenue related to the sale of future royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues							8,545		2,692	0
Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues							5,088		78	35,809
Kyowa Kirin | Non-cash royalty revenue related to the sale of future royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 3,400			3,400
Kyowa Kirin | 2017 KKC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees			$ 30,000
Potential development milestones													$ 55,000
Total revenues													35,000
Potential commercialization milestones							$ 54,500				$ 54,500	$ 54,500	54,500	¥ 8,500.0
Period to reduce royalty rate							2 years	2 years
Fee receivable for reduction in royalty rate							$ 40,000				$ 40,000	$ 40,000	$ 40,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche							2				2	2	2	2
Kyowa Kirin | 2017 KKC Agreement | Non-cash royalty revenue related to the sale of future royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					¥ 500.0		$ 8,545		2,692	0
Kyowa Kirin | 2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues							$ 0		0	30,000
Fosun Pharma | Fosun Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received		$ 12,000
Potential development and commercialization milestones												$ 113,000
Proceeds from milestone payments												$ 13,000
Threshold percentage of net sales for tiered royalties							20.00%	20.00%
Fosun Pharma | Fosun Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues						$ 5,000	$ 5,000		0	5,000
Knight | Knight Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees	$ 2,300
Potential development milestones							700
Potential development and commercialization milestones							16,200	$ 22.2
Knight | Knight Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues							$ 88		78	59
AstraZeneca | AZ Termination Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty revenue							10.00%	10.00%
Percentage of non royalty revenue							20.00%	20.00%
Maximum potential payment per agreement															$ 75,000
Cost of revenue							$ 12,700		34,700	12,400
METiS Therapeutics Inc | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues							$ 0		$ 0	$ 750
Proceeds from milestone payments											$ 243,000
Upfront payment																$ 800